Perspective Therapeutics Brings Energy to the Radiopharma World
Seattle-based Perspective Therapeutics came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, signaling growing momentum in targeted radiopharmaceuticals.
One of the company’s molecules, VMT-α-NET, a therapy for neuroendocrine tumors (NETs), achieved a 50% objective response rate, which is significantly higher than the standard 13% for NETs. “It’s exciting for me to see a field I’ve been a part of for a long time to see a surge,” said Michael Schultz, chief science officer and co-founder of Perspective Therapeutics. “To be here [at ASCO] and see it being presented with such great results to such a huge community is a dream come true.”
These advances reinforce Seattle’s growing role as a hub for radiopharmaceutical development and manufacturing.